The melanocytes attacked by the autoimmune disease are present in the eyes and ears, not just the skin, so vitiligo can adversely affect vision and hearing.
Vitiligo is an autoimmune disorder that attacks melanocytes, which are cells that produce pigment in the body. In individuals with vitiligo, the destroy melanocytes leads to the loss of pigment and results in white patches on the body. These are more prominent on dark skin.
On the surface, vitiligo may appear to be a cosmetic condition, but its effects run deeper and affect other parts of the body besides the skin. In addition to psychological burdens, such as social stigma and self-esteem issues, individuals with vitiligo may also have physiological complications, including thyroid problems, other immune diseases, and ocular or auditory issues.
Studies have shown that approximately 20% of people with vitiligo also have other autoimmune conditions. Thyroid disorders, such as Graves’ disease and Hashimoto’s disease, are the most common. Other autoimmune disorders associated with vitiligo can include type 1 diabetes, alopecia areata, rheumatoid arthritis, pernicious anemia and systemic sclerosis.
In addition to skin epithelium, melanocytes are also present in the retina and uvea of the eye. One component of the uvea is the iris, which is the pigmented part of the eye. Vitiligo affecting the eyes can cause retinitis and iritis. Patients may experience light sensitivity, eye discomfort, and vision disturbances. If left untreated, these complications may lead to glaucoma and vision loss.
Melanocytes are also present in the cochlea found in the inner ear. In some cases of vitiligo, immune cells attack cochlear melanocytes, causing hearing loss. It is estimated that between 12% and 38% of people with vitiligo have some hearing loss.
It is evident that vitiligo is more than a dermatological condition. An interprofessional approach to treatment is essential for people living with vitiligo. Those who present with concurrent autoimmune disorders would benefit from referrals to appropriate specialists for additional treatment. Routine eye and ear exams may also be part of treatment plans in order to preserve vision and hearing and minimize further complications.
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
Opzelura Provides Benefit in Atopic Dermatitis in Real-World Studies | AAD 2024
March 8th 2024Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.
Read More
Reasons for attending the AAD meeting | AAD 2024
March 7th 2024John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.
Read More
FDA Approves First-in-Class Cell Treatment for Patients With Advanced Melanoma
February 19th 2024Amtagvi was approved to treat patients with advanced melanoma. It is a one-time cell therapy that will be administered at authorized treatment centers and have a wholesale acquisition cost of $515,000.
Read More